Subjects | 32 (46) | 38 (54) | | |
Severe asthma cases | 11 (34) | 23 (60) | | 0.03* |
Age years | 49 (45–58) | 48 (44–62) | −1 (−5–9) | 0.64 |
Sex | | | | 0.34 |
Male | 18 | 16 | | |
Female | 14 | 22 | | |
Asthma onset years | 28 (10–40) | 26 (14–31) | −2 (−10–7) | 0.81 |
Late-onset asthma (≥18 years) | 20 (62) | 24 (63) | | 1.00 |
Asthma duration years | 19 (13–30) | 23 (17–34) | 3 (−4–11) | 0.35 |
Smokers (≥10 pack-years)# | 11 (34) | 7 (18) | | 0.17 |
Atopy | 19 (59) | 25 (66) | | 0.62 |
Serum IgE IU·L−1 | 108 (57–163) | 132 (49–187) | 24 (−54–53) | 0.77 |
Polysensitivity (>1 allergen) | 17 (53) | 21 (55) | | 0.68 |
Sensitisation to perennial allergens | 12 (37) | 16 (42) | | 0.81 |
Sensitisation to Mycophyta | 3 (9) | 6 (16) | | 0.49 |
Sinusitis | 15 (50)¶ | 23 (60) | | 0.62 |
BMI kg·m−2 | 26.9 (24.8–27.9) | 25.2 (24.1–26.3) | −1.8 (−2.9–1.1) | 0.35 |
FEV1 % pred | 82 (78–91) | 77 (71–83) | −5 (−13–1) | 0.11 |
FVC % pred | 98 (90–102) | 81 (55–96) | −16 (−34– −1) | 0.03* |
ΔFEV1 post-β2-agonist mL | 355 (260–420) | 245 (210–300) | −110 (−150– −20) | 0.004* |
ΔFVC post-β2-agonist mL | 280 (220–350) | 290 (210–430) | 10 (−60–170) | 0.15 |
RV % pred | 102 (97–139) | 118 (104–148) | 16 (−3–24) | 0.11 |
FRC % pred | 97 (87–110) | 107 (101–122) | 10 (1–24) | 0.04* |
FEV1/FVC % | 66 (59–76) | 64 (57–69) | −2 (−12–1) | 0.08 |
RV/TLC % | 34 (32–38) | 38 (34–44) | 3 (−1–8) | 0.06 |
FENO ppb | 30 (21–37) | 19 (15–29) | −11 (−16–3) | 0.14 |
Exacerbations per year | 1 (0–1) | 1 (1–2) | 0 (0–1) | 0.02* |
Frequent exacerbators (>1 per year) | 9 (28) | 17 (45) | | 0.21 |
ICS daily dose µg | 160 (100–400) | 400 (200–480) | 240 (40–300) | 0.004* |
OCS | 1 (3) | 7 (18) | | 0.06 |
Blood neutrophils mL−1 | 3435 (2910–3910) | 3480 (3080–3810) | 45 (−560–481) | 0.95 |
Blood neutrophils % | 54 (50–59) | 50 (48–53) | −3 (−7–0) | 0.10 |
Blood eosinophils mL−1 | 250 (180–350) | 200 (130–370) | −50 (−110–70) | 0.71 |
Blood eosinophils % | 3 (3–5) | 3 (3–5) | −1 (−1–1) | 0.51 |